-
1.
公开(公告)号:US12097242B2
公开(公告)日:2024-09-24
申请号:US17721569
申请日:2022-04-15
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
CPC classification number: A61K38/18 , A61K38/2221 , C07K1/1077 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号:US11408093B2
公开(公告)日:2022-08-09
申请号:US16813094
申请日:2020-03-09
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jonathan Davis , Dasa Lipovsek , Ray Camphausen
IPC: C40B40/08 , C07K16/24 , C07K16/28 , C07K14/78 , C07K14/47 , G01N33/68 , C12N15/10 , C40B40/10 , A61K38/00
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号:US11364281B2
公开(公告)日:2022-06-21
申请号:US17198939
申请日:2021-03-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
公开(公告)号:US11203630B2
公开(公告)日:2021-12-21
申请号:US16549462
申请日:2019-08-23
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Tracy S. Mitchell , Michael L. Gosselin , Dasa Lipovsek , Rex Parker , Ray Camphausen , Jonathan H. Davis , David Fabrizio
IPC: C07H21/04 , C12P21/06 , C12N15/87 , C12N5/20 , C12N1/20 , C12N15/00 , C07K14/78 , A61K47/64 , A61K38/00
Abstract: The present invention relates to polypeptides which include tenth fibronectin type III domains (10Fn3) that binds to serum albumin, with south pole loop substitutions. The invention further relates to fusion molecules comprising a serum albumin-binding 10Fn3 joined to a heterologous protein for use in diagnostic and therapeutic applications.
-
公开(公告)号:US10584160B2
公开(公告)日:2020-03-10
申请号:US15760449
申请日:2016-09-22
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Dasa Lipovsek , Joseph Toth , Ginger C. Rakestraw , Irvith M. Carvajal , Stanley Richard Krystek, Jr. , Steven R. O'Neil , Guodong Chen , Richard Y. Huang , Bryan C. Barnhart , John Thomas Loffredo , Christina Terragni
Abstract: Provided herein are polypeptides which include tenth fibronectin type III domains (10Fn3) that bind to glypican-3. Also provided are fusion molecules comprising a 10Fn3 domain that bind to glypican-3 for use in diagnostic and therapeutic applications. Glypican-3 10Fn3 drug conjugates are also provided.
-
公开(公告)号:US10450363B2
公开(公告)日:2019-10-22
申请号:US15127183
申请日:2015-03-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Dasa Lipovsek
Abstract: Provided herein are proteins comprising a fibronectin based scaffold (FBS) domain, e.g., 10Fn3 molecules, that bind specifically to a target, and wherein the FBS domain is linked at its C-terminus to a region consisting of PmXn, wherein P is proline, X is any amino acid and wherein n is 0 or an integer that is at least 1 and m is an integer that is at least 1, and wherein the PmXn moiety provides an enhanced property to the FBS domain, e.g., enhanced stability, relative to the protein that is not linked to the PmXn moiety.
-
公开(公告)号:US10406212B2
公开(公告)日:2019-09-10
申请号:US15491271
申请日:2017-04-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Sharon Cload , Linda Engle , Dasa Lipovsek , Malavi Madireddi , Ginger Chao Rakestraw , Joanna Swain , Wenjun Zhao , Alexander T. Kozhich , Martin J. Corbett
IPC: C07K14/00 , A61K38/39 , C07K14/78 , C07K16/46 , A61K45/06 , G01N33/74 , C07K14/435 , C07K14/765 , C07K14/79 , C07K16/18 , A61K38/17 , A61K47/64 , A61K47/60 , A61K38/00
Abstract: The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins.
-
8.
公开(公告)号:US20130245238A1
公开(公告)日:2013-09-19
申请号:US13757668
申请日:2013-02-01
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Jonathan DAVIS , Dasa Lipovsek , Ray Camphausen
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
Abstract translation: 提供了具有与降低的免疫原性相关的新颖设计的纤连蛋白III型(10Fn3)结合结构域。 本申请描述了替代的10Fn3结合结构域,其中当产生粘合剂时,某些免疫原性区域不被修饰,以便由宿主生物保持识别为自身抗原。 该应用还描述了其中HLA锚定区已经被破坏的10Fn3结合结构域,从而降低相邻区域的免疫原性贡献。 还提供了10Fn3结构域,其具有可以高亲和力结合所需靶的修饰区域的新颖组合。
-
公开(公告)号:US20130196871A1
公开(公告)日:2013-08-01
申请号:US13757664
申请日:2013-02-01
Applicant: Bristol-Myers Squibb Company
Inventor: Jonathan Davis , Dasa Lipovsek , Ray Camphausen
CPC classification number: C07K14/78 , A61K38/00 , C07K14/47 , C07K16/241 , C07K16/244 , C07K16/28 , C07K16/2833 , C07K16/2857 , C07K2317/92 , C07K2318/20 , C12N15/1062 , C40B40/10 , G01N33/68 , G01N33/6887
Abstract: Fibronectin type III (10Fn3) binding domains having novel designs that are associated with reduced immunogenicity are provided. The application describes alternative 10Fn3 binding domains in which certain immunogenic regions are not modified when producing a binder in order to maintain recognition as a self antigen by the host organism. The application also describes 10Fn3 binding domains in which HLA anchor regions have been destroyed thereby reducing the immunogenic contribution of the adjoining region. Also provided are 10Fn3 domains having novel combinations of modified regions that can bind to a desired target with high affinity.
-
公开(公告)号:US12097241B2
公开(公告)日:2024-09-24
申请号:US17573238
申请日:2022-01-11
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor: Gene M. Dubowchik , Olafur S. Gudmundsson , Xiaojun Han , R. Michael Lawrence , Dasa Lipovsek , Cort S. Madsen , Claudio Mapelli , Paul E. Morin , Michael C. Myers
CPC classification number: A61K38/18 , A61K38/2221 , C07K1/1077 , C07K14/64 , A61K38/00 , A61K45/06 , A61K47/64 , A61P9/00
Abstract: The present disclosure generally relates to modified relaxin polypeptides, such as modified human relaxin 2 polypeptides, comprising a non-naturally encoded amino acid which is linked to a pharmacokinetic enhancer, and therapeutic uses of such polypeptides, such as for the treatment of cardiovascular conditions (such as heart failure) and/or conditions relating to fibrosis.
-
-
-
-
-
-
-
-
-